Literature DB >> 23558880

Arrhythmogenic effect of flecainide toxicity.

Pierre-Yves Nd Courand1, Franck Sibellas, Sylvain Ranc, Audrey Mullier, Gilbert Kirkorian, Eric Bonnefoy.   

Abstract

Flecainide is a class 1C antiarrhythmic drug especially used for the management of supraventricular arrhythmia. In overdose cases, flecainide can induce life treating ventricular arrhythmias and cardiogenic shock. We report the case of a 72-year-old woman admitted to our intensive care unit for a regular monomorphic wide complex tachycardia (QRS duration 240 ms, right bundle branch block and superior axis morphology) without apparent P waves. Clinical examination showed slight left congestive heart failure signs without cardiogenic shock. An intravenous bolus of 10 mg adenosine 5'-triphosphate (ATP) was ineffective to stop the tachycardia. The diagnosis of ventricular tachycardia induced by flecainide overdose was considered. 500 mL of intravenous 84‰ sodium bicarbonate was administrated. The patient's QRS narrowed immediately and 12-lead ECG showed sinus rhythm. Blood samples confirmed the flecainide overdose and the clinical status progressively improved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23558880     DOI: 10.5603/CJ.2013.0035

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  2 in total

Review 1.  The Role of Sodium Bicarbonate in the Management of Some Toxic Ingestions.

Authors:  Aibek E Mirrakhimov; Taha Ayach; Aram Barbaryan; Goutham Talari; Romil Chadha; Adam Gray
Journal:  Int J Nephrol       Date:  2017-08-08

2.  Efficacy and safety of 1C class antiarrhythmic agent (propafenone) for supraventricular arrhythmias in septic shock compared to amiodarone: protocol of a prospective randomised double-blind study.

Authors:  Martin Balik; Petr Waldauf; Michal Maly; Vojtech Matousek; Tomas Brozek; Jan Rulisek; Michal Porizka; Robert Sachl; Michal Otahal; Petr Brestovansky; Eva Svobodova; Marek Flaksa; Zdenek Stach; Jaroslav Pazout; Frantisek Duska; Ondrej Smid; Martin Stritesky
Journal:  BMJ Open       Date:  2019-09-03       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.